Research Experience for Undergraduates
Announcements
Custom Synthesis of Metal/Porous Nanoparticles
Nanotoxicology
Biomedical Image Contrast Agents
Precision Nanoprobes
Molecular Nanotechnology
Custom Synthesis of Metal/Porous Nanoparticles
Standardized synthesis of Gold nanoparticles (nanoclusters, 5 nm, 10 nm, 16 nm) Silver nanoparticles (nanoclusters, 10 nm, 40 nm, 95 nm) Iron oxide nanoparticles (10 nm) Gadolinium oxide (5 nm, 10 nm) Hafnium oxide (5 nm, 10 nm) Microporous silica particles (15 nm, 50 nm, 100 nm, 400 nm) Other nanoparticles currently being optimized include …
Nanotoxicology
Nanotoxicity assessment is an integral part of designing biomedical probes. In vitro toxicity of nanoparticles is assessed using murine (L929) and human cell lines (HUVEC, RAW246.7). In vivo toxicity was assessed in zebrafish models, and in vivo biodistribution/blood pool kinetics was assessed in athymic and euthymic mouse models. Representative Publications …
Biomedical Image Contrast Agents
Scaled up the synthesis of nanoparticle contrast agents. I specialize in the synthesis of long emission lifetime, fluorescent and photoluminescent nanoparticles. This is achieved by modifying Au cores with fluorophore embedded shells or Au nanoclusters with tunable photoluminescence. Fluorescent silica particles with sizes ranging from 15 nm to 400 nm are also available. Such probes …
Precision Nanoprobes
Antibody-drug conjugates are emerging as a frontrunner in precision targeted therapeutics. However, this capability is still beyond the ability of most academic laboratories. The primary reason for this is the need to identify a precise binding site on the constant region of the antibody (Fc) for the drug molecule to be conjugated, while not affecting …
Molecular Nanotechnology
This is the current focus of my research. Utilizing anisotropic and hybrid nanoparticle architectures to introduce directionality in motion, precisely orienting targeting molecules and directed exertion of force by nanosystems. Anisotropic nanoparticles can be Janus hybrids or non-spherical nanoparticles and include rods, plates, prisms, and core-shells. This will lay the basis for nanomotors and nanomachines …
Excited to be Funded by the Institute for Precision Health’s Harvest Grant
The University of Notre Dame’s Institute for Precision Health (IPH) has awarded funding to researchers spanning multiple departments at the University, as well as to colleagues at partner schools. IPH awarded proposals with two types of funding: seed grants, which provide funding for high-risk, high-reward research ideas, and harvest grants, which help researchers expand on established projects or pursue …
ACS-Institutional Research Grant -Phase II Grant Funded to Mitigate Cardiotoxicity of Chemotherapeutics using our Nanocarriers
Excited that our phase-II proposal to the American Cancer Society’s Institutional Research Grant (ACS-IRG) program was funded. This was upon successful phase I completion of our proposal for a novel magnetically driven drug nanocarrier. We propose to use these drug nanocarriers to mitigate cardiotoxicity in the new study. The data generated by the study funded …
NIH Funding Opportunities
- An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immunogenicity in Severe Hemophilia A: Hemophilia A Analytical Cohort Research Program (UG3/UH3 Clinical Trial Not Allowed) September 9, 2021Funding Opportunity RFA-HL-22-004 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support applications that propose the establishment of a Hemophilia A Analytical Cohort Research Program (HARP) that will: 1) collaborate with an established consortium of clinical centers to support the recruitment, enrollment, and follow-up of an antenatal/ neonatal/ […]
- Making Health Care Safer in Ambulatory Care Settings and Long-term Care Facilities (R18) September 9, 2021Funding Opportunity PA-21-267 from the NIH Guide for Grants and Contracts. The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make […]
- Notice of Correction to the Key Date Section in PAR-21-320, "NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)" September 9, 2021Notice NOT-DA-21-080 from the NIH Guide for Grants and Contracts
- Notice of NHLBI Participation in PAR-21-154, "Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required)" September 9, 2021Notice NOT-HL-21-031 from the NIH Guide for Grants and Contracts
- Notice of Special Interest (NOSI): Evaluation of sex differences on HIV-associated comorbidities in the context of stimulant use September 9, 2021Notice NOT-DA-21-020 from the NIH Guide for Grants and Contracts
- Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (U24 Clinical Trial Required) September 8, 2021Notice NOT-CA-21-112 from the NIH Guide for Grants and Contracts
- Notice of Intent to Publish a Funding Opportunity Announcement for Research Bases for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required) September 8, 2021Notice NOT-CA-21-113 from the NIH Guide for Grants and Contracts
- Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required) September 8, 2021Notice NOT-CA-21-114 from the NIH Guide for Grants and Contracts
- Emerging Global Leader Award (K43 Independent Clinical Trial Required) September 8, 2021Funding Opportunity PAR-21-251 from the NIH Guide for Grants and Contracts. This is a reissue of the Emerging Global Leader Program (K43) to align with the clinical trials policy.
- Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) September 8, 2021Funding Opportunity PAR-21-252 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience […]
Recent Comments